Application based on the pivotal Phase 3 TRANSFORM study in which Breyanzi showed significant and clinically meaningful improvements over salvage chemotherapy followed by high-dose chemotherapy plus autologous stem cell transplant, which has been the standard of care for more than 20 years
It will open new frontier for south-to-south collaboration and innovation transfer
On track to complete the BLA submission in the first half of 2022
The vaccine will be priced at Rs. 265 per dose and the applicator being offered at Rs. 93 per dose excluding GST
A National Tele Mental Health Programme is being launched to address mental health issues. We spoke to healthcare industry leaders who shared their outlook
APS03118 is a novel innovative drug developed by APS with global independent intellectual property rights for unlimited cancer types
Pfizer is evaluating the FDA’s comments and will work with the agency to determine an appropriate path forward
The acquisition would enable addition of established brands with high recall amongst healthcare professionals, especially in the vitamins, minerals and supplements category
This surpasses the number of approvals supported in 2020
Application based on DESTINY-Breast03 results showing Daiichi Sankyo and AstraZeneca’s trastuzumab deruxtecan reduced risk of disease progression or death by 72% versus trastuzumab emtansine (T-DM1)
Subscribe To Our Newsletter & Stay Updated
